TY - JOUR AU - Hendrickson, Andrea Wahner AU - Meng, Xue Wei AU - Kaufmann, Scott H. T1 - Anticancer therapy: boosting the bang of Bim PY - 2008/11/03/ AB - Even though activating mutations of B-Raf, a kinase atop the MAPK signaling cascade, reportedly sensitize tumor cells to MEK inhibitors, Raf and MEK inhibitors have exhibited limited clinical activity. In this issue of the JCI, Cragg et al. report that MEK inhibition upregulates the proapoptotic Bcl-2 family member Bim but induces little regression of human melanoma xenografts in mice unless the Bcl-2 antagonist ABT-737 is added (see the related article beginning on page 3651). These findings illustrate the potential benefit of simultaneously inhibiting oncogenic kinases and inhibiting Bcl-2 action in solid tumors. JF - The Journal of Clinical Investigation JA - J Clin Invest SN - 0021-9738 DO - 10.1172/JCI37553 VL - 118 IS - 11 UR - https://doi.org/10.1172/JCI37553 SP - 3582 EP - 3584 PB - The American Society for Clinical Investigation ER -